Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose nab-paclitaxel plus tislelizumab in previously treated elderly advanced non-small cell lung cancer
ChiCTR2100046698Phase 2Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Changzhou Second People's Hospital. Primary endpoints: progression-free survival and safety. Started Jan 2019; status: recruiting.
02
Drugs
paclitaxeltislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100046698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046698.